Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
compound kushen injection + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of compound kushen injection (CKI), a traditional Chinese medicine formulation, and pembrolizumab, an immune checkpoint inhibitor. CKI is derived from the roots of Sophora flavescens (Kushen) and has demonstrated anti-cancer properties through various mechanisms including immunomodulation. Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, enhancing T-cell immune responses against cancer cells. The combination may potentially offer synergistic effects by combining CKI's immunomodulatory and anti-tumor properties with pembrolizumab's immune checkpoint inhibition.
- Brand names
- Keytruda
- Other names
- CKI + pembrolizumabcompound kushen injection + pabolizumabCompound Kushen Injection Combined With Pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on compound kushen injection + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on compound kushen injection + pembrolizumab.